For­mer ex­ecs from Pfiz­er obe­si­ty drug pro­gram have start­ed a new biotech with $52M from VC fund ATP

Two for­mer chem­istry VPs who worked at Pfiz­er’s car­dio­vas­cu­lar and meta­bol­ic re­search group have come to­geth­er to build a new biotech as the obe­si­ty drug de­vel­op­ment field soars.

The start­up, called Deep Ap­ple Ther­a­peu­tics, has a lead pro­gram that goes af­ter an undis­closed in­flam­ma­to­ry skin dis­ease and will en­ter the clin­ic around 2025, but its lot­tery tick­et is an oral small mol­e­cule triple G (GLP-1/GIP/glucagon) for obe­si­ty and oth­er non-GLP-1 pro­grams for meta­bol­ic dis­or­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER